• Aucun résultat trouvé

Annex 3. Potentially overlapping toxicities of antiretrovirals and anti-tuberculosis agents (including first-line anti-tuberculosis agents)

N/A
N/A
Protected

Academic year: 2022

Partager "Annex 3. Potentially overlapping toxicities of antiretrovirals and anti-tuberculosis agents (including first-line anti-tuberculosis agents)"

Copied!
2
0
0

Texte intégral

(1)

1

Annex 3

Annex 3. Potentially overlapping toxicities of antiretrovirals and anti-tuberculosis agents (including first-line anti-tuberculosis agents)

Potential toxicity Antiretroviral therapy Anti-tuberculosis therapy Peripheral neuropathy stavudine cycloserine

  didanosine isoniazid

    ethambutol

    fluoroquinolones

    streptomycin

    kanamycin

    amikacin

    capreomycin

    viomycin

    ethionamide/prothionamide

    linezolid

Psychiatric symptoms efavirenz cycloserine

    isoniazid

    fluoroquinolones

    ethionamide/prothionamide

Hepatitis nevirapine pyrazinamide

  ritonavir-boosted protease

inhibitors isoniazid

  efavirenz rifampicin/rifabutin

  etravirine p-aminosalicylic acid

  maraviroc ethionamide/prothionamide

    fluoroquinolones

WHO/HTM/TB/2011.6c

(2)

2

Annex 3

Annex 3 (continued)

Potential toxicity Antiretroviral therapy Anti-tuberculosis therapy Gastrointestinal intolerance

       

zidovudine ethionamide/prothionamide protease inhibitors p-aminosalicylic acid

didanosine pyrazinamide

  isoniazid

  rifampicin

  ethambutol

  clofazimine

Renal toxicity  

   

tenofovir streptomycin

indinavir kanamycin

  capreomycin

  amikacin

  viomycin

rifampicin Bone marrow toxicity zidovudine linezolid

rifampicin/rifabutin Lactic acidosis

 

stavudine linezolid

didanosine  

zidovudine  

Stevens–Johnson syndrome  

   

nevirapine thioacetazone

efavirenz cycloserine

etravirine linezolid

  ethambutol

  streptomycin

Arrhythmias / QT prolongation   

atazanavir/ritonavir fluoroquinolones saquinavir/ritonavir  

lopinavir/ritonavir  

Rash / pruritus nevirapine rifampicin/rifabutin

efavirenz pyrazinamide

etravirine  

abacavir  

Références

Documents relatifs

and z in the linear coefficient, or slope.. 19 Table 2: Results of univariate linear regressions of log number of pathogen species classified by

Gaydoz, Jean Baptiste — Gaydo, Jean Baptiste Gaye, Anta Germaine (Aïssatou Germaine Anta), sene- gales.. normale supérieure

Using these concentrations of Bevacizumab and SU1498, the doubling times of U87 cell population were 21.1, 21.5 and 26.3 hours respectively for control, Bevacizumab- and SU1498-

We evaluated the effect of the TNF antagonists infliximab (Ifx), adalimumab (Ada) and etanercept (Eta) on anti-mycobacterial immune responses in two conditions: with ex vivo

(2002) il est mentionné que les infirmières ressentent l’envi d’en savoir beaucoup plus sur la toxicomanie et seraient heureuses de pouvoir suivre des formations

Une bactérie qui développe spontanément une mutation conférant la résistance à un antibiotique mais qui ne perturbe pas ou peu la structure et donc la fonction biologique de cette

The process can also be applied to find the pose of sensors relative to a robot frame, if the relative motion of the robot body can be observed (e.g., using inertial and odometry

Comme nous l’avons également mentionné dans le Chapitre 1 de ce manuscrit (cf. Partie E, §1), de nombreux travaux ont porté sur l’amélioration des capacités de piégeage de la